|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We found that the TNF-alpha-308A allele frequency was significantly decreased among patients with early-onset psoriasis in comparison with control subjects (7.5% vs. 15.4%, P = 0.022), whereas in the same patients the frequency of the TNF-alpha-238A allele was significantly increased as compared with the controls (16.8% vs. 3.1%, P = 0.000017, odds ratio 8.79, 95% confidence interval 2.606-29.678).
|
17553030 |
2007 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This suggests that TNFA gene promoter polymorphism in the region examined is less associated with the pathogenesis of psoriasis in Japanese patients, however there might be the possibility that TNFA gene promoter polymorphism is associated with GPP.
|
12234707 |
2002 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
FCGR3A-V158F polymorphism is a disease-specific pharmacogenetic marker for the treatment of psoriasis with Fc-containing TNFα inhibitors.
|
27044681 |
2017 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Psoriasis and Psoriasiform Eruptions in Pediatric Patients with Inflammatory Bowel Disease Treated with Anti-Tumor Necrosis Factor Alpha Agents.
|
28211161 |
2017 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We analyzed three SNPs in IL-17A (rs2275913 and rs10484879) and IL-17F (rs763780) to look for an association with psoriasis and/or with response to anti-TNF drugs or ustekinumab.
|
26415694 |
2015 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The meta-analysis suggests that TNF-α 308 G/A polymorphism is associated with decreased risk of psoriasis, while TNF-α 238 G/A is associated with increased risk of psoriasis.
|
24324571 |
2013 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These skin-infiltrating lymphocytes might trigger, by the local production of Th-1 cytokines such as TNF-alpha and interferon-gamma (IFN-gamma), the eruption of psoriatic plaques in patients with a genetic predisposition for psoriasis.
|
16441627 |
2006 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To examine whether initiation of interleukin (IL)-17, IL-12/23 or tumour necrosis factor (TNF) inhibitor is associated with an increased risk of serious infection among real-world psoriasis (PsO) or psoriatic arthritis (PsA) patients.
|
31672774 |
2020 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Analysis of gene expression confirmed dysregulation in all expected functional categories, such as IFN signaling and keratinocyte differentiation, and allowed molecular fingerprinting of a previously characterized dendritic cell subset associated with psoriasis tumor necrosis factor alpha (TNF-alpha)- and inducible nitric oxide synthase (iNOS)-producing CD11b(INT) DC (Tip-DC).
|
17637826 |
2008 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our aim was to evaluate the effect of DNA variants at the "TNFα pathway" that could affect the risk of developing Psoriasis or the response to biological therapies among these patients.
|
25537528 |
2015 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We aimed to determine whether Cw6 and the genetic polymorphism of the CDSN gene, POU5F1 gene, MICA gene and the gene for TNF-alpha promoter region were associated with an increased risk of psoriasis in Chinese patients.
|
12653732 |
2003 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Biologics licensed for psoriasis include the TNFα inhibitors (infliximab, adalimumab, etanercept), the interleukin (IL)-12/23 monoclonal antibody (ustekinumab), and IL-17 inhibitor (secukinumab, ixekizumab).
|
29299984 |
2017 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
IL-36γ expression is enhanced by tumor necrosis factor-α and IL-17A, having a strong association with psoriasis.
|
29314201 |
2018 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this study, we report association of response of psoriasis to TNF blockers with two TNFAIP3 single-nucleotide polymorphisms (rs2230926 in exon 7 and rs610604 in intron 3) and their haplotypes.
|
22113471 |
2012 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PCR Real time Mismatch Amplification Mutation Assay (MAMA Real Time PCR) for evaluation of TNF-α promoter gene polymorphism -308 G/A in patients with psoriasis.
|
26584427 |
2016 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Patients with psoriasis and psoriatic arthritis respond well to tumor necrosis factor alpha (TNFalpha) blockers in general; however, there is now mounting evidence that a small cohort of patients with rheumatoid arthritis who receive TNFalpha blockers develop psoriasis.
|
20112373 |
2010 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our primary objective was to assess the HPV DNA prevalence in psoriasis patients treated with TNF inhibitors and the secondary objective was to assess the same parameter before and during treatment.
|
24206262 |
2014 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
When we compared type I psoriasis with type II psoriasis (N = 36), we found a significant association between age at onset and the genes PSORS6, TNF-α, FCGR2A, TNFR1, CD226, HLA-C, TNFAIP3, and CCHCR1.
|
26613086 |
2015 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We performed a case-control study of 69 patients with psoriasis type I and 70 controls, characterized clinical progression along 10-years of follow-up in mild or severe disease and determined HLA class I, II, and TNF single nucleotide polymorphisms (SNPs) -238 and -308 polymorphisms to demonstrate whether these polymorphisms may be genetic risk for susceptibility to psoriasis or severity of the disease in Brazilians.
|
20931685 |
2010 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We found that there were a three-way interaction among IL21, CCR4 and TNF(χ(2) = 5.02(1), P = 0.025) and three pair-wise gene-gene interactions between IL12RB1 and CCR4(χ(2) = 11.66(4), P = 0.0201), IL22 and CCR4 (χ(2) = 11.97(4), P = 0.0176), IL12RB1 and IL6 (χ(2) = 7.31(1), P = 0.0069) in psoriasis.
|
22909235 |
2013 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our results support an association between susceptibility to psoriasis and TNF polymorphisms in the Spanish population.
|
24135300 |
2014 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To describe the use of tumor necrosis factor-alpha inhibitors (TNFis) among pregnancies ending in a live birth and with a diagnosis of ankylosing spondylitis (AS), Crohn's disease (CD), juvenile idiopathic arthritis (JIA), psoriasis (PsO), psoriatic arthritis (PsA), rheumatoid arthritis (RA), or ulcerative colitis (UC).
|
30430682 |
2019 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Among a cohort of Danish patients with moderate-to-severe psoriasis, two SNPs in the IL12B and TNF genes were associated with susceptibility of psoriasis.
|
29389950 |
2018 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Stratification by disease type indicated an association between the TNFRSF1B rs1061622 allele and non-responders to TNF antagonist in RA (T/G OR 0.69, 95% CI 0.48-0.99, p<0.05) and psoriasis (T/G OR 0.39, 95% CI 0.23-0.67, p<0.001), but not in CD (T/G OR 1.14, 95% CI 0.57-0.93, p=0.57).
|
26071216 |
2015 |
|
Psoriasis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Cardiovascular event risk assessment in psoriasis patients treated with tumor necrosis factor-α inhibitors versus methotrexate.
|
27894789 |
2017 |